This possibility is supported by Fear et al.41 who demonstrated that GITR agonist decreased tumor growth in a murine subcutaneous mesothelioma model and by our recent study demonstrating that greater number of CD8+ T cells were associated with better survival in epithelioid mesothelioma but not in biphasic mesothelioma after the SMART approach42. The gene discussed is CD8A; the disease is malignant biphasic mesothelioma.